| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2012 | ECSTASY, an adjustable membrane-tethered/soluble protein expression system for the directed evolution of mammalian proteins. | Chen, CP; Hsieh, YT; Prijovich, ZM; Chuang, HY; Chen, KC; Lu, WC; Tseng, Q; Leu, YL; Cheng, TL; Roffler, SR | PROTEIN ENGINEERING DESIGN & SELECTION 25(7), 367-375 | | | |
| 2015 | Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity. | Hsieh, YT; Lin, HP; Chen, BM; Huang, PT; Roffler, SR | PloS one 10(10), e0141088 | | | |
| 2010 | Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. | Chuang, KH; Wang, HE; Chen, FM; Tzou, SC; Cheng, CM; Chang, YC; Tseng, WL; Shiea, J; Lin, SR; Wang, JY; Chen, BM; Roffler, SR; Cheng, TL | Molecular cancer therapeutics 9(6), 1903-1912 | | | |
| 2017 | Endothelial SCUBE2 Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis. | Lin, YC; Chao, TY; Yeh, CT; Roffler, SR; Kannagi, R; Yang, RB | ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 37(1):144-155 | | | |
| 2011 | Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of beta-glucuronidase in tumors. | Huang, PT; Chen, KC; Prijovich, ZM; Cheng, TL; Leu, YL; Roffler, SR | Cancer gene therapy 18(6), 381-389 | | | |
| 1991 | Extractive Bioconversions with Nonaqueous Solvents | Roffler, SR; Randolph, TW; Miller, DA; Blanch, HW; Prausnitz, JM | Extractive Bioconversions (USA : Marcel Dekker Inc) | | | |
| 2009 | Hapten-derivatized nanoparticle targeting and imaging of gene expression by multimodality imaging systems. | Cheng, CM; Chu, PY; Chuang, KH; Roffler, SR; Kao, CH; Tseng, WL; Shiea, J; Chang, WD; Su, YC; Chen, BM; Wang, YM; Cheng, TL | Cancer Gene Therapy 16, 83-90 | | | |
| 2014 | High-throughput sorting of the highest producing cell via a transiently protein-anchored system. | Chuang, KH; Hsieh, YC; Chiang, IS; Chuang, CH; Kao, CH; Cheng, TC; Wang, YT; Lin, WW; Chen, BM; Roffler, SR; Huang, MY; Cheng, TL | PloS one 9(7), e102569 | | | |
| 2015 | Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy. | Hsieh, YT; Chen, KC; Cheng, CM; Cheng, TL; Tao, MH; Roffler, SR | PloS one 10(2), e0118028 | | | |
| 2011 | In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a non-inhibitory protease substrate. | Cheng, TL; Chuang, CH; Chuang, KH; Wang, HE; Roffler, SR; Shiea, JT; Tzou, SC; Wu, SY; Cheng, TC; Kao, CH; Cheng, CM; Tseng, WL; Hou, MF; Wang, JM | CLINICAL CANCER RESEARCH 18(1), 238-247 | | | |
| 2009 | Local enzymatic hydrolysis of an endogenously-generated metabolite can enhance CPT-11 anti-cancer efficacy | Prijovich, ZM; Chen, KC; Roffler, SR | Molecular Cancer Research 8(4), 940-946 | | | |
| 2010 | Measurement of poly(ethylene glycol) by cell-based anti-poly(ethylene glycol) ELISA. | Chuang, KH; Tzou, SC; Cheng, TC; Kao, CH; Tseng, WL; Shiea, J; Liao, KW; Wang, YM; Chang, YC; Huang, BJ; Wu, CJ; Chu, PY; Roffler, SR; Cheng, TL | Analytical chemistry 82(6), 2355-2362 | | | |
| 2016 | Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. | Chen, BM; Su, YC; Chang, CJ; Burnouf, PA; Chuang, KH; Chen, CH; Cheng, TL; Chen, YT; Wu, JY; Roffler, SR | Analytical chemistry 88(21), 10661-10666 | | | |
| 2005 | Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. | Cheng, TL; Cheng, CM; Chen, BM; Tsao, DA; Chuang, KH; Hsiao, SW; Lin, YH; Roffler, SR | Bioconjugate Chemistry 16, 1225-1231 | | | |
| 2014 | One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. | Kao, CH; Wang, JY; Chuang, KH; Chuang, CH; Cheng, TC; Hsieh, YC; Tseng, YL; Chen, BM; Roffler, SR; Cheng, TL | Biomaterials 35(37), 9930-9940 | | | |
| 2014 | PET Imaging of beta-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy. | Su, YC; Cheng, TC; Leu, YL; Roffler, SR; Wang, JY; Chuang, CH; Kao, CH; Chen, KC; Wang, HE; Cheng, TL | Molecular Cancer Therapeutics 13(12), 2852-2863 | | | |
| 2016 | Reloadable multidrug capturing delivery system for targeted ischemic disease treatment | Wu, JP; Cheng, B; Roffler, SR; Lundy, DJ; Yen, CY; Chen, P; Lai, JJ; Pun, SH; Stayton, PS; Hsieh, PC | Science Translational Medicine 8(365), 365ra160 | | | |
| 2015 | Selective Delivery of PEGylated Compounds to Tumor Cells by anti-PEG Hybrid Antibodies. | Tung, HY; Su, YC; Chen, BM; Burnouf, PA; Huang, WC; Chuang, KH; Yan, YT; Cheng, TL; Roffler, SR | Molecular cancer therapeutics Epub ahead of print | | | |
| 2010 | Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. | Su, YC; Chen, BM; Chuang, KH; Cheng, TL; Roffler, SR | Bioconjugate chemistry 21(7), 1264-1270 | | | |
| 2016 | Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation. | Prijovich, ZM; Burnouf, PA; Chou, HC; Huang, PT; Chen, KC; Cheng, TL; Leu, YL; Roffler, SR | Molecular pharmaceutics 13(4), 1242-50 | | | |
